Hepato-gastroenterologie HK, s.r.o.

Hradec Králové 50012

9 studies enrolling now · 56 studies all time

What they study most

Colitis, Ulcerative, Crohn Disease, Crohn's Disease, Moderately to Severely Active Crohn Disease, Moderately to Severely Active Crohns Disease, Moderately to Severely Active Ulcerative Colitis, Primary Biliary Cholangitis, Primary Biliary Cholangitis (PBC), Small Bowel Crohn's Disease, Ulcerative Colitis

Studies at this site

• A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis — Recruiting now
• A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis — Recruiting now
• A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease — Recruiting now
• A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis — Recruiting now
• A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease — Recruiting now
• A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease — Recruiting now
• A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease — Recruiting now
• A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD) — Recruiting now
• Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease — Recruiting now
• A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease — Running, not enrolling
• Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients — Running, not enrolling
• A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. — Completed
• An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis — Running, not enrolling
• ABTECT - Maintenance — Running, not enrolling
• A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease — Stopped early
• To Evaluate Safety and Tolerability of the Fixed- Dose Combination of Obeticholic Acid and Bezafibrate — Stopped early
• A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis — Running, not enrolling
• A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis — Completed
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC) — Stopped early
• Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis — Stopped early
• Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis — Completed
• ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1 — Completed
• A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's Disease — Stopped early
• Etrasimod Versus Placebo for the Treatment of Moderately Active Ulcerative Colitis — Completed
• Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year — Completed
• A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's Disease — Completed
• A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease — Completed
• Open-Label Extension and Safety Study for Participants With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144 — Stopped early
• Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's Disease — Completed
• Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies — Stopped early
• Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease — Completed
• Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis — Completed
• Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis — Completed
• A Study to Assess Whether Etrolizumab is a Safe and Efficacious Treatment for Participants With Moderately to Severely Active Crohn's Disease — Completed
• A Study of Mirikizumab (LY3074828) in Participants With Active Crohn's Disease — Completed
• Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis — Completed
• Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease (CD) — Completed
• Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy in Ulcerative Colitis — Completed
• Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis — Completed
• Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis — Completed
• Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD) — Completed
• A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors — Completed
• A Study of the Efficacy and Safety of Etrolizumab in Participants With Ulcerative Colitis Who Have Been Previously Exposed to Tumor Necrosis Factor (TNF) Inhibitors — Completed
• A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors — Completed
• Study to Evaluate the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis — Completed
• BI 695501 Versus Humira in Patients With Active Crohn's Disease: a Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity — Completed
• Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis — Completed
• An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis — Completed
• Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease — Stopped early
• A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease — Withdrawn before enrolling